Editas Medicine Beheer

Beheer criteriumcontroles 2/4

De CEO Editas Medicine is Gilmore O’Neill, benoemd in Jun2022, heeft een ambtstermijn van 2.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.39M, bestaande uit 26.8% salaris en 73.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde $ 315.58K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.7 jaar en 3.9 jaar.

Belangrijke informatie

Gilmore O’Neill

Algemeen directeur

US$2.4m

Totale compensatie

Percentage CEO-salaris	26.8%
Dienstverband CEO	2.4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25

Analyse CEO-vergoeding

Hoe is Gilmore O’Neill's beloning veranderd ten opzichte van Editas Medicine's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$193m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$2m	US$641k	-US$153m
Sep 30 2023	n/a	n/a	-US$195m
Jun 30 2023	n/a	n/a	-US$206m
Mar 31 2023	n/a	n/a	-US$219m
Dec 31 2022	US$9m	US$356k	-US$220m

Compensatie versus markt: De totale vergoeding ($USD 2.39M ) Gilmore } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.48M ).

Compensatie versus inkomsten: De vergoeding van Gilmore is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Gilmore O’Neill (60 yo)

2.4yrs

Tenure

US$2,392,309

Compensatie

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gilmore O’Neill	President	2.4yrs	US$2.39m	0.13% $ 315.6k
Erick Lucera	CFO & Executive VP	1.5yrs	US$2.69m	0.028% $ 67.2k
Linda Burkly	Executive VP & Chief Scientific Officer	1.3yrs	US$1.73m	0.018% $ 42.1k
Baisong Mei	Executive VP & Chief Medical Officer	2.3yrs	US$1.14m	0.052% $ 123.8k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	11.8yrs	geen gegevens	geen gegevens
George Church	Co-Founder & Scientific Advisory Board Member	11.8yrs	geen gegevens	geen gegevens
Gregory Whitehead	Executive VP and Chief Technical & Quality Officer	less than a year	geen gegevens	geen gegevens
Cristi Barnett	Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Charlene Stern	Executive VP & General Counsel	no data	geen gegevens	geen gegevens
Linea Aspesi	Executive VP & Chief People Officer	1.7yrs	geen gegevens	geen gegevens
Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	1.2yrs	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EDIT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gilmore O’Neill	President	no data	US$2.39m	0.13% $ 315.6k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
George Church	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Emma Reeve	Independent Chairman of the Board	3.2yrs	US$238.24k	0% $ 0
Andrew Hirsch	Independent Director	7.5yrs	US$210.56k	0.0024% $ 5.8k
Jessica Hopfield	Independent Director	6.8yrs	US$231.07k	0.082% $ 197.0k
Elliott Levy	Independent Director	1.6yrs	US$264.88k	0% $ 0
David Scadden	Independent Director	5.8yrs	US$213.06k	0% $ 0
Bernadette Connaughton	Independent Director	3.1yrs	US$215.06k	0% $ 0
Meeta Chatterjee	Independent Director	3.9yrs	US$205.56k	0% $ 0

3.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EDIT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Editas Medicine Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

President recently sold US$67k worth of stock

President notifies of intention to sell stock

CFO & Executive VP recently sold US$125k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Recent updates

Price target decreased by 7.1% to US$13.00

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Consensus revenue estimates fall by 13%

New major risk - Revenue and earnings growth

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Insider selling

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

President notifies of intention to sell stock

CFO & Executive VP recently sold US$125k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Consensus revenue estimates fall by 16%

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

First quarter 2024 earnings: EPS and revenues miss analyst expectations

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Consensus revenue estimates increase by 14%

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO, Principal Accounting Officer notifies of intention to sell stock

Price target decreased by 8.6% to US$13.06

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Principal Accounting Officer notifies of intention to sell stock

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Price target decreased to US$14.19

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Price target decreased to US$16.73

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Editas Medicine started at neutral at BofA due to competition in gene editing programs

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations